Site
Search results (Showing 1 - 10 of 25 results)
-
References | 5 Nov 2015
The Impact of Increasing Multiple Sclerosis (Ms) Severity Level on Employment and Caregiver Burden.
-
References | 6 Mar 2016
Central Neuropathic Pain Syndromes.
Watson JC, Sandroni PMayo Clin Proc. 2016 Mar; 91(3):372-85. PMID: 26944242. Abstract -
References | 22 May 2016
Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the US.
Watson C, Bonafede MM, Johnson BHValue Health. 2014 Nov; 17(7):A391. PMID: 27200903. Abstract -
References | 1 Jul 1995
Central defects of autonomic function in secondary progressive multiple sclerosis: observations based on cardiovascular and growth hormone responses to clonidine.
Thomaides TN, Zoukos Y, Chaudhuri KR, Watson L, Mathias CJEur J Neurol. 1995 Jul; 2(3):163-9. PMID: 24283632. Abstract -
References | 20 Oct 2015
Modeling The Natural History of Secondary-Progressive Multiple Sclerosis: A New Modeling Approach Using Discrete Event Simulation.
Hernandez L, Guo S, Altincatal A, Naoshy S, Watson CValue Health. 2015 Nov; 18(7):A700. Epub 2015 Oct 20. PMID: 26533922. Abstract -
References | 19 Dec 2013
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
Bonafede MM, Johnson BH, Watson CClinicoecon Outcomes Res. 2013; 6:11-20. Epub 2013 Dec 19. PMID: 24379685. Abstract -
References | 27 Jun 2015
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Johnson BH, Bonafede MM, Watson CCNS Drugs. 2015 Jun 26. PMID: 26113055. Abstract -
References | 20 Oct 2015
Using A Mixed Methods Approach to Develop A Discrete Choice Experiment In Multiple Sclerosis.
Padania S, Bottomley CJ, Adlard N, Watson J, Lloyd AValue Health. 2015 Nov; 18(7):A761. Epub 2015 Oct 20. PMID: 26534263. Abstract -
References | 25 Oct 2012
Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs.
Watson CT, Disanto G, Breden F, Giovannoni G, Ramagopalan SVSci Rep. 2012; 2:770. Epub 2012 Oct 25. PMID: 23105968. Abstract -
References | 20 Dec 2012
Protection of tregs, suppression of Th1 and th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.
Mondal S, Martinson JA, Ghosh S, Watson R, Pahan KPLoS One. 2012; 7(12):e51869. Epub 2012 Dec 20. PMID: 23284794. Abstract